» Articles » PMID: 24887517

MiR-21 Overexpression Enhances TGF-β1-induced Epithelial-to-mesenchymal Transition by Target Smad7 and Aggravates Renal Damage in Diabetic Nephropathy

Overview
Date 2014 Jun 3
PMID 24887517
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial-to-mesenchymal transition (EMT) plays an important role in renal interstitial fibrosis (RIF) with diabetic nephropathy (DN). Smad7 (a inhibitory smad), a downstream signaling molecules of TGF-β1, represses the EMT. The physiological function of miR-21 is closely linked to EMT and RIF. However, it remained unclear whether miR-21 over-expression affected TGF-β1-induced EMT by regulating smad7 in DN. In this study, real-time RT-PCR, cell transfection, luciferase reporter gene assays, western blot and confocal microscope were used, respectively. Here, we found that miR-21 expression was upregulated by TGF-β1 in time- and concentration -dependent manner. Moreover, miR-21 over-expression enhanced TGF-β1-induced EMT(upregulation of a-SMA and downregulation of E-cadherin) by directly down-regulating smad7/p-smad7 and indirectly up-regulating smad3/p-smad3, accompanied by the decrease of Ccr and the increase of col-IV, FN, the content of collagen fibers, RTBM, RTIAW and ACR. Meantime, the siRNA experiment showed that smad7 can directly regulate a-SMA and E-cadherin expression. More importantly, miR-21 inhibitor can not only inhibit EMT and fibrosis but also ameliorate renal structure and function. In conclusion, our results demonstrated that miR-21 overexpression can contribute to TGF-β1-induced EMT by inhibiting target smad7, and that targeting miR-21 may be a better alternative to directly suppress TGF-β1-mediated fibrosis in DN.

Citing Articles

Enrichment of RedoxifibromiR miR-21-5p in Plasma Exosomes of Hypertensive Patients with Renal Injury.

Martinez-Arroyo O, Flores-Chova A, Mendez-Debaets M, Martinez-Hervas S, Martinez F, Forner M Int J Mol Sci. 2025; 26(2).

PMID: 39859307 PMC: 11765217. DOI: 10.3390/ijms26020590.


Research progress in anti-renal fibrosis drugs.

Huang H, Peng Z, Yuan Q Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025; 49(8):1353-1362.

PMID: 39788524 PMC: 11628227. DOI: 10.11817/j.issn.1672-7347.2024.240284.


MiR-192-5p targets cell cycle regulation in diabetic kidney disease via cyclin-dependent kinase inhibitor 3.

Sahoo B, Mishra D, Tiwari S Noncoding RNA Res. 2024; 11:60-72.

PMID: 39736853 PMC: 11683246. DOI: 10.1016/j.ncrna.2024.11.003.


Significance of plasma TGF-β1 level detection in patients with T2DM with heart failure.

Sun Y, Miao B, Cao Y, Cui J, Da Y, Qi L J Med Biochem. 2024; 43(5):704-710.

PMID: 39712502 PMC: 11662957. DOI: 10.5937/jomb0-47321.


Novel therapeutic target for diabetic kidney disease through downregulation of miRNA-192-5p and miRNA-21-5p by celastrol: implication of autophagy, oxidative stress, and fibrosis.

Al-Tantawy S, Eraky S, Eissa L Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39702603 DOI: 10.1007/s00210-024-03669-5.